Literature DB >> 17107981

African-American and Hispanic ethnicities, renal involvement and obesity predispose to hypertension in systemic lupus erythematosus: results from LUMINA, a multiethnic cohort (LUMINAXLV).

Sumapa Chaiamnuay1, Ana M Bertoli, Jeffrey M Roseman, Gerald McGwin, Mandar Apte, Sergio Durán, Luis M Vilá, John D Reveille, Graciela S Alarcón.   

Abstract

OBJECTIVE: To examine the predictors of the occurrence of hypertension in a large multiethnic US cohort. PATIENTS AND METHODS: There were 614 patients with systemic lupus erythematoses (SLE; > or = 4 American College of Rheumatology revised criteria) with < or = 5 years of disease duration at entry into the cohort (T0) and of Hispanic (Texan or Puerto Rican), African-American or Caucasian ethnicity. T0 variables were compared between patients who did and did not develop hypertension (blood pressure > or = 140/90 mm Hg on at least two occasions and/or the use of antihypertensive drugs) after T0. Significant and clinically relevant variables were then examined by a stepwise logistic regression model.
RESULTS: A total of 379 patients without hypertension at T0 were included (patients who developed hypertension prior to SLE diagnosis (n = 126) or before T0 (n = 109) were excluded). Predictors of hypertension were African-American and Texan-Hispanic ethnicities, renal involvement and a higher body mass index.
CONCLUSIONS: Traditional cardiovascular risk factors, disease-related factors and ethnicity play a role in the occurrence of hypertension in patients with SLE. Controlling renal involvement and optimising body weight may prevent the occurrence of hypertension.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17107981      PMCID: PMC1954629          DOI: 10.1136/ard.2006.059311

Source DB:  PubMed          Journal:  Ann Rheum Dis        ISSN: 0003-4967            Impact factor:   19.103


  45 in total

1.  Special report. The Second International Anti-cardiolipin Standardization Workshop/the Kingston Anti-Phospholipid Antibody Study (KAPS) group.

Authors:  E N Harris
Journal:  Am J Clin Pathol       Date:  1990-10       Impact factor: 2.493

2.  The bimodal mortality pattern of systemic lupus erythematosus.

Authors:  M B Urowitz; A A Bookman; B E Koehler; D A Gordon; H A Smythe; M A Ogryzlo
Journal:  Am J Med       Date:  1976-02       Impact factor: 4.965

3.  Systemic lupus erythematosus in a multiethnic US cohort (LUMINA) XL II: factors predictive of new or worsening proteinuria.

Authors:  H M Bastian; G S Alarcón; J M Roseman; G McGwin; L M Vilá; B J Fessler; J D Reveille
Journal:  Rheumatology (Oxford)       Date:  2006-11-28       Impact factor: 7.580

4.  Premature coronary-artery atherosclerosis in systemic lupus erythematosus.

Authors:  Yu Asanuma; Annette Oeser; Ayumi K Shintani; Elizabeth Turner; Nancy Olsen; Sergio Fazio; MacRae F Linton; Paolo Raggi; C Michael Stein
Journal:  N Engl J Med       Date:  2003-12-18       Impact factor: 91.245

5.  Morbidity in systemic lupus erythematosus.

Authors:  D D Gladman; M B Urowitz
Journal:  J Rheumatol Suppl       Date:  1987-06

6.  Immunology of DNA. III. Crithidia luciliae, a simple substrate for the determination of anti-dsDNA with the immunofluorescence technique.

Authors:  L A Aarden; E R de Groot; T E Feltkamp
Journal:  Ann N Y Acad Sci       Date:  1975-06-30       Impact factor: 5.691

7.  Antiphospholipid antibodies are associated with an increased risk for chronic renal insufficiency in patients with lupus nephritis.

Authors:  Gabriella Moroni; Donatella Ventura; Paola Riva; Paola Panzeri; Silvana Quaglini; Giovanni Banfi; Paola Simonini; Rossella Bader; Pier Luigi Meroni; Claudio Ponticelli
Journal:  Am J Kidney Dis       Date:  2004-01       Impact factor: 8.860

8.  Risk factors for coronary artery disease in patients with systemic lupus erythematosus.

Authors:  M Petri; S Perez-Gutthann; D Spence; M C Hochberg
Journal:  Am J Med       Date:  1992-11       Impact factor: 4.965

9.  Low levels of total cholesterol, high-density lipoprotein, and apolipoprotein A1 in association with anticardiolipin antibodies in patients with systemic lupus erythematosus.

Authors:  R G Lahita; E Rivkin; I Cavanagh; P Romano
Journal:  Arthritis Rheum       Date:  1993-11

10.  Risk factors for subclinical atherosclerosis in a prospective cohort of patients with systemic lupus erythematosus.

Authors:  A Doria; Y Shoenfeld; R Wu; P F Gambari; M Puato; A Ghirardello; B Gilburd; S Corbanese; M Patnaik; S Zampieri; J B Peter; E Favaretto; L Iaccarino; Y Sherer; S Todesco; P Pauletto
Journal:  Ann Rheum Dis       Date:  2003-11       Impact factor: 19.103

View more
  16 in total

1.  Cardiovascular and disease-related predictors of depression in systemic lupus erythematosus.

Authors:  Laura J Julian; Chris Tonner; Ed Yelin; Jinoos Yazdany; Laura Trupin; Lindsey A Criswell; Patricia P Katz
Journal:  Arthritis Care Res (Hoboken)       Date:  2011-04       Impact factor: 4.794

2.  Correlation between systemic lupus erythematosus and malignancies: a cross-sectional population-based study.

Authors:  Shir Azrielant; Shmuel Tiosano; Abdulla Watad; Naim Mahroum; Aaron Whitby; Doron Comaneshter; Arnon D Cohen; Howard Amital
Journal:  Immunol Res       Date:  2017-04       Impact factor: 2.829

Review 3.  Understanding mechanisms of hypertension in systemic lupus erythematosus.

Authors:  Erin B Taylor; Michael J Ryan
Journal:  Ther Adv Cardiovasc Dis       Date:  2016-03-15

4.  Increased Incidence of Resistant Hypertension in Patients With Systemic Lupus Erythematosus: A Retrospective Cohort Study.

Authors:  Jocelyn S Gandelman; Omair A Khan; Megan M Shuey; Jacquelyn E Neal; Elizabeth McNeer; Alyson Dickson; April Barnado; Li Wang; Prathima Anandi; William D Dupont; C Michael Stein; Cecilia P Chung
Journal:  Arthritis Care Res (Hoboken)       Date:  2020-04       Impact factor: 4.794

Review 5.  Hypertension in connective tissue disease.

Authors:  Qiang Luo; Yiwen Zhang; Xiaoqian Yang; Li Qin; Han Wang
Journal:  J Hum Hypertens       Date:  2022-05-03       Impact factor: 3.012

Review 6.  Autoimmune-mediated renal disease and hypertension.

Authors:  Erika I Boesen; Rahul M Kakalij
Journal:  Clin Sci (Lond)       Date:  2021-09-17       Impact factor: 6.876

7.  The impact of obesity on SLE disease activity: findings from the Southern California Lupus Registry (SCOLR).

Authors:  Phildrich Teh; Bishoy Zakhary; Vaneet K Sandhu
Journal:  Clin Rheumatol       Date:  2018-10-24       Impact factor: 2.980

8.  Long-term prognosis and factors associated with damage accrual in Japanese patients with systemic lupus erythematosus.

Authors:  Yoko Wada; Hisashi Hasegawa; Takako Saeki; Satoshi Ito; Takeshi Kuroda; Masaaki Nakano; Ichiei Narita
Journal:  Clin Exp Nephrol       Date:  2017-10-25       Impact factor: 2.801

Review 9.  Disparities in lupus care and outcomes.

Authors:  Kristina L Demas; Karen H Costenbader
Journal:  Curr Opin Rheumatol       Date:  2009-03       Impact factor: 5.006

Review 10.  Inflammation, obesity and rheumatic disease: common mechanistic links. A narrative review.

Authors:  Elena Nikiphorou; George E Fragoulis
Journal:  Ther Adv Musculoskelet Dis       Date:  2018-06-27       Impact factor: 5.346

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.